India is set to see cheaper weight-loss drugs as Semaglutide's patent expires on March 20, 2026. Used in Ozempic and Wegovy, the drug may cost up to 50% less as Indian firms launch generics. Prices could drop to ₹5,000 per dose, boosting demand, though experts warn against unsupervised use.